Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523 | 0.98 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL2879833 | 0.94 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL102472 | 0.90 | POLB (0.41) | SMN1; SMN2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1972216 | 0.82 | TSHR (0.40) | ALDH1A1TSHRKDM4EMAPTMEN1 | |
| SCHEMBL1709463 | 0.82 | OPRM1 (0.48) | SMN1; SMN2ALDH1A1TSHRKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL1283011 | 0.81 | OPRM1 (0.47) | ALDH1A1TSHRKDM4EMAPTMEN1 | |
| SCHEMBL15166914 | 0.81 | POLB (0.38) | SMN1; SMN2ALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL1709447 | 0.80 | OPRM1 (0.35) | SMN1; SMN2ALDH1A1TSHRKMT2AOPRM1 | |
| SCHEMBL9606533 | 0.79 | CYP1A2 (0.40) | SMN1; SMN2ALDH1A1KDM4EMAPTPOLB | |
| SCHEMBL18871066 | 0.79 | NPSR1 (0.44) | ALDH1A1MAPTMEN1KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON, INC. (KR) | 2025-10-07 | — | — | US | disclosed |
| CN-116234552-B | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2025-02-25 | — | — | CN | disclosed |
| US-20240360092-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | VIVOZON INC. (KR) | 2024-10-31 | — | — | US | disclosed |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | VIVOZON INC. (KR) | 2024-08-13 | — | — | US | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| EP-4190770-A1 | DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF | Vivozon, Inc. (KR) | 2023-06-07 | — | — | EP | disclosed |
| EP-4190770-A1 | DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF | Vivozon, Inc. (KR) | 2023-06-07 | — | — | EP | disclosed |
| CN-116234552-A | Dual modulators of mGluR5 and 5-HT2A receptors and uses thereof | (株)倍宝尊 | 2023-06-06 | — | — | CN | disclosed |
| US-20220274939-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | VIVOZON INC. (KR) | 2022-09-01 | — | — | US | disclosed |
| WO-2022025636-A1 | DUAL REGULATOR FOR MGLUR5 AND 5-HT2A RECEPTORS AND USE THEREOF | 주식회사 비보존 | 2022-02-03 | — | — | WO | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1359915-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-11-12 | — | — | EP | disclosed |
| EP-1351687-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002058702-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-08-01 | — | — | WO | disclosed |
| WO-2002047456-A2 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5955487-A | TREATING HIGH BLOOD PRESSURE, CARDIAC INSUFFICIENCY, GLAUCOMA | CIBA-GEIGY CORPORATION (US) | 1999-09-21 | — | — | US | disclosed |
| US-5620998-A | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-04-15 | — | — | US | disclosed |
| US-5506240-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435051-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | GRM5, HTR5A, HTR2A | SMN1; SMN2 2445/4885ALDH1A1 3972/4885TSHR 611/4885 |
| US-20240360092-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | GRM5, HTR5A, HTR2A | SMN1; SMN2 2445/4885ALDH1A1 3972/4885TSHR 611/4885 |
| US-12060339-B2 | Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof | GRM5, HTR5A, HTR2A | SMN1; SMN2 2445/4885ALDH1A1 3972/4885TSHR 611/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | SMN1; SMN2 2206/4885ALDH1A1 3733/4885TSHR 3953/4885 |
| US-20220274939-A1 | DUAL MODULATOR OF MGLUR5 AND 5-HT2A RECEPTOR, AND USE THEREOF | GRM5, HTR5A, HTR2A | SMN1; SMN2 2445/4885ALDH1A1 3972/4885TSHR 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.